Reta + Tesamorelin Blend

This is an injectable blend of two very different research compounds: Retatrutide (a GLP-1/GIP/glucagon triple agonist from metabolic research) and Tesamorelin (a GHRH analog meant to nudge the body's own growth-hormone release). Both have their own lexikon entries as single originals - that is where the solid evidence lives.

Honest framing up front: this is an experimental construct. It ships as a freeze-dried powder that you reconstitute with bacteriostatic water and inject subcutaneously - the same route on which both compounds were given in the studies. The catch is the fixed 1:1 mix (10 mg reta + 10 mg tesa per vial): the two peptides have completely different typical weekly doses, so one shared dose never fits both at once. There is no human study on this exact combination - neither for efficacy nor for the ideal dose. What you read here contextualizes the pharmacology, but it cannot substitute for combination data that simply does not exist.

This information is for research and educational purposes only. No medical recommendations.

On paper these are two completely separate mechanisms:

• Retatrutide activates three receptors at once - GLP-1, GIP and glucagon. Studies point to appetite suppression, slowed gastric emptying, and, via the glucagon arm, increased energy expenditure.
• Tesamorelin mimics GHRH and is meant to prompt the pituitary to release growth hormone in pulses, which raises IGF-1 levels. In a research context it has mainly been linked to reduction of visceral abdominal fat.

The crucial catch with the fixed mix: reta already works in the range of a few milligrams per week, whereas tesamorelin is given in studies in the milligram range per day. In a 50/50 vial you cannot hit both in their sensible range at the same time - dose for reta and the tesa amount is low; dose for tesa and the reta amount quickly gets too high. Pharmacologically this blend is therefore a compromise, not an optimized combination product.

For the combination itself there is nothing - no clinical trials, no pharmacokinetic data, no efficacy evidence for this exact reta-plus-tesa vial. That has to be stated plainly.

What does exist is robust data on the single originals (each subcutaneous):

• Retatrutide: In a 48-week phase 2 trial (subcutaneous, weekly), the highest dose produced a mean weight reduction of around 24% versus placebo. A meta-analysis across 878 patients confirmed marked effects on weight and metabolic parameters.
• Tesamorelin: Phase 3 trials in patients with visceral fat accumulation showed a roughly 15 to 18% reduction in visceral fat over 6 to 12 months (subcutaneous, daily), plus a rise in IGF-1, with generally good tolerability.

These findings are for each mono-application at its own study-typical dose. Whether a fixed 50/50 mix, in which neither runs in its ideal range, delivers the same effects is an open question.

Because there is no data on the combination, side effects can only be inferred from the single originals:

• From the retatrutide arm (GLP-1/GIP/glucagon): In the studies, gastrointestinal effects dominated - nausea, vomiting, diarrhea, constipation. They were dose-dependent and mostly mild to moderate. Dose-dependent increases in heart rate were also observed.
• From the tesamorelin arm (GHRH): Reported items include injection-site reactions, joint and limb complaints, fluid retention and occasional tingling. Glucose parameters stayed largely stable in the trials.

In the fixed blend both profiles add up, and because the reta share limits first when you dose up, GI complaints are the most likely reason you cannot go higher. No safety profile exists for this exact combination - there is correspondingly a lot of uncertainty in play.

Plain-language framing: this blend is an experimental setup, not a mature combination product. Anyone looking for the solid research on Retatrutide or Tesamorelin should look at the individual lexikon entries for the two originals - that is where the entire body of evidence sits.

• Reta and tesa have very different typical doses - a fixed 1:1 mix never hits both ideally at once.
• Dose reta-anchored (the potent share first), otherwise you risk a reta overdose while chasing more tesa.
• No human data on the combination also means: no statement on long-term safety of this exact mix.

If you specifically want to push one of the two mechanisms, the individual injectable entries are the more honest and cleaner starting point. This blend stays experimental.

Store the unopened, freeze-dried vial cool and dark. After reconstitution it belongs in the fridge (2 to 8 °C) and should be used within a few weeks. Bacteriostatic water as the solvent inhibits microbial growth. Do not freeze, protect from heat and direct light.